# Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

> **NCT06694701** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hellenic Institute for the Study of Sepsis** · enrollment: 75 (estimated)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Emapalumab-Izsg
- **DRUG:** Emapalumab-Izsg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06694701
- **Lead sponsor:** Hellenic Institute for the Study of Sepsis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-22
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06694701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06694701, "Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06694701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*